^
    CANCER:

    Cervical Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    bevacizumab-bvzr
    bevacizumab-tnjn
    bevacizumab-awwb
    		0
    VEGF-A inhibitor
    bevacizumab-adcd
    bevacizumab-maly
    Aybintio (bevacizumab biosimilar)
    Krabeva (bevacizumab biosimilar)
    bevacizumab
    PD1 inhibitor
    pembrolizumab
    cemiplimab-rwlc
    		1
    PD1 inhibitor
    AGEN2034
    zimberelimab
    nivolumab
    geptanolimab
    serplulimab
    cisplatin
    		2
    DNA synthesis inhibitor
    mitomycin
    gemcitabine
    3
    Topoisomerase I inhibitor
    topotecan
    irinotecan
    4
    PD1 inhibitor, CTLA4 inhibitor
    cadonilimab
    nivolumab + ipilimumab
    5
    Tubulin polymerization promoter, Bcl2 inhibitor
    carboplatin + paclitaxel
    paclitaxel
    6
    Microtubule inhibitor, Human TF-targeted antibody-drug conjugate
    tisotumab vedotin-tftv
    7
    Thymidylate synthase inhibitor
    5-fluorouracil
    8
    Tubulin polymerization promoter
    carboplatin
    9
    Tubulin polymerization inhibitor
    vinorelbine tartrate
    10
    Bifunctional alkylating agent
    ifosfamide
    11
    Bcl2 inhibitor, Tubulin inhibitor
    albumin-bound paclitaxel
    12
    Topoisomerase II inhibitor, DNA inhibitor, DNA synthesis inhibitor
    cisplatin + etoposide oral
    13
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    capecitabine + mitomycin
    14
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    anlotinib + sintilimab
    anlotinib + penpulimab
    15
    VEGFR-2 inhibitor, PD1 inhibitor
    camrelizumab + rivoceranib
    16
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    17
    VEGF-A inhibitor, PARP inhibitor
    bevacizumab + olaparib
    bevacizumab + rucaparib
    18
    FGFR inhibitor
    ABSK091
    19
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki
    20
    VEGF inhibitor
    recombinant human endostatin
    21
    ATR inhibitor
    BAY 1895344
    22
    RET inhibitor
    selpercatinib
    23
    PIK3CA inhibitor
    alpelisib
    EP
    TPB
    		24
    Chemotherapy
    CP
    CaT
    CPB
    VC
    25
    PARP inhibitor
    PARP inhibitor
    olaparib
    26
    Immunotherapy
    Immunotherapy
    27
    Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor
    cisplatin + paclitaxel
    28
    VEGF-A inhibitor, PD1 inhibitor
    pembrolizumab + bevacizumab
    29
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    30
    Topoisomerase II inhibitor, Tubulin polymerization promoter, DNA inhibitor
    carboplatin + etoposide oral
    31
    DNA synthesis inhibitor, Topoisomerase I inhibitor
    cisplatin + topotecan
    32
    THF dehydrogenase inhibitor, Thymidylate synthase inhibitor
    pemetrexed
    33
    Tubulin polymerization promoter, Bcl2 inhibitor, Topoisomerase I inhibitor
    paclitaxel + topotecan
    34
    PD1 inhibitor, CTLA4 antagonist
    AGEN2034 + UGN-301
    35
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    36
    Immunostimulant, PD1 inhibitor
    pembrolizumab + tirvalimogene teraplasmid
    37
    PD1 inhibitor, IDO1 inhibitor
    nivolumab + BMS-986205
    38
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    neratinib
    afatinib
    39
    VEGFR inhibitor, PD1 inhibitor
    sintilimab + fruquintinib
    40
    TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    sacituzumab govitecan-hziy
    41
    PIK3CA inhibitor, HER2 inhibitor, HER4 inhibitor, EGFR inhibitor, PI3Kδ inhibitor
    neratinib + copanlisib
    42
    Nucleolin inhibitor
    QN-165
    43
    HER2 inhibitor
    trastuzumab
    44
    5T4-targeted antibody-drug conjugate, Microtubule inhibitor
    ASN004
    45
    BET inhibitor, BRD4 inhibitor
    GS-626510
    46
    β-catenin inhibitor, CBP inhibitor, Microtubule inhibitor
    eribulin mesylate
    47
    CTLA4 inhibitor
    ipilimumab
    48
    CA6-targeted antibody-drug conjugate, Microtubule inhibitor
    SAR566658
    49
    mTOR inhibitor
    sirolimus
    No biomarker
    PD-L1 expression
    PD-L1 negative
    PD-L1 overexpression
    PD-L1 amplification
    PIK3CA mutation
    HER-2 mutation
    PIK3CA E545K
    HER-2 expression
    HER-2 positive
    HER-2 overexpression
    NTRK3 fusion
    MSI-H/dMMR
    NTRK2 fusion
    FGFR3-TACC3 F17T8
    KMT2D mutation
    KDR expression
    PD-L1 expression + KMT2D mutation
    PD-L1 expression + PIK3CA mutation
    ARID1A mutation
    TMB-H
    RPS26 expression
    CLPTM1L expression
    BRCA2 exon 11 deletion
    BRCA1 mutation + TP53 R248Q
    BRCA1 positive
    PIK3CA E542Q + TMB-H + MSI-H/dMMR
    NTRK1 fusion
    RET fusion
    DDR
    IFNG gene signature overexpression
    TROP2 expression
    BAX overexpression
    TUBB3 overexpression
    PRDX2 overexpression
    TPBG expression
    NCL overexpression
    TBX1 overexpression
    AJUBA overexpression
    ITM2A overexpression
    STK11 mutation
    ROR1 expression
    TXN overexpression
    IL6 elevation
    MAPK4 deletion
    TNFA elevation
    PER2 overexpression
    PD-L1 expression + JAK2 mutation
    PD-L1 expression + STK11 mutation + JAK2 mutation
    PD-L1 expression + STK11 mutation
    RAD51 underexpression
    HUWE1 mutation
    CXCL8 elevation
    MYC overexpression
    DIRAS3 overexpression
    PRDX1 overexpression
    CA6 expression